Guggenheim Lowers Inventiva (NASDAQ:IVA) Price Target to $9.00

Inventiva (NASDAQ:IVA) had its price objective lowered by equities research analysts at Guggenheim from $12.00 to $9.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 193.16% from the stock’s current price.

A number of other equities research analysts have also issued reports on the company. TD Cowen assumed coverage on Inventiva in a research report on Friday, February 21st. They issued a “buy” rating and a $10.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Inventiva in a report on Friday, March 28th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $12.00.

Inventiva Price Performance

IVA opened at $3.07 on Friday. The business’s 50-day moving average price is $2.77 and its two-hundred day moving average price is $2.51. Inventiva has a 1 year low of $1.53 and a 1 year high of $3.98.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.